Supplementary Table from PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN

Supplementary Table 1. Patient demographic and clinical characteristics Supplementary Table 2. Associations of PD-L1 expression with response to therapy Supplementary Table 3. Treatment comparison on ORR and DCR, subgroup analysis by PD-L1 expression status on tumor cells (TC) Supplementary Table 4. Treatment comparison on PFS and OS, subgroup analysis by PD-L1 expression status on tumor cells (TC), immune cells (IC) or TC/IC combined scores*. Supplementary Table 5. Associations of MET and/or PD-L1 expression on tumor cells with treatment outcomes Supplementary Table 6. Treatment comparison on PFS and OS, subgroup analysis by MET and PD-L1 ({greater than or equal to}1% cutoff) expression on tumor cells Supplementary Table 7. Association of immune cell density (ICD) tertile groups* with PFS, OS, ORR and DCR Supplementary Table 8. Association of immune cell density (ICD) continuous scores with PFS and OS Supplementary Table 9. Treatment comparison on PFS and OS, subgroup analysis by immune cell density (ICD) (dichotomized at the upper 33% tertile value from the joint distribution of two trials)